TW201033181A - Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine - Google Patents
Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine Download PDFInfo
- Publication number
- TW201033181A TW201033181A TW099103300A TW99103300A TW201033181A TW 201033181 A TW201033181 A TW 201033181A TW 099103300 A TW099103300 A TW 099103300A TW 99103300 A TW99103300 A TW 99103300A TW 201033181 A TW201033181 A TW 201033181A
- Authority
- TW
- Taiwan
- Prior art keywords
- phenyl
- hbr
- isopropanol
- salt
- solvent
- Prior art date
Links
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title abstract description 3
- 238000000746 purification Methods 0.000 title description 13
- 238000000034 method Methods 0.000 claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 100
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 89
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 81
- 239000012453 solvate Substances 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 48
- 239000002904 solvent Substances 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 20
- -1 THF ketone Chemical class 0.000 claims description 12
- 239000012535 impurity Substances 0.000 claims description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 7
- WHTJRGLVQCFHBN-UHFFFAOYSA-N hydron;propan-2-ol;bromide Chemical compound Br.CC(C)O WHTJRGLVQCFHBN-UHFFFAOYSA-N 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 241000009298 Trigla lyra Species 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 3
- KZTYYGOKRVBIMI-UHFFFAOYSA-N diphenyl sulfone Chemical group C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 KZTYYGOKRVBIMI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000006193 liquid solution Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 claims 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 10
- 239000000243 solution Substances 0.000 description 39
- 239000013078 crystal Substances 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- ROFVJSWBDQUQGW-UHFFFAOYSA-N piperidin-1-ium;bromide Chemical compound Br.C1CCNCC1 ROFVJSWBDQUQGW-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 7
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- NDKJATAIMQKTPM-UHFFFAOYSA-N 2,3-dimethylbenzenethiol Chemical compound CC1=CC=CC(S)=C1C NDKJATAIMQKTPM-UHFFFAOYSA-N 0.000 description 2
- AMNLXDDJGGTIPL-UHFFFAOYSA-N 2,4-dimethylbenzenethiol Chemical compound CC1=CC=C(S)C(C)=C1 AMNLXDDJGGTIPL-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical group C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
- IVSZLXZYQVIEFR-UHFFFAOYSA-N 1,3-Dimethylbenzene Natural products CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 1
- OIRHKGBNGGSCGS-UHFFFAOYSA-N 1-bromo-2-iodobenzene Chemical compound BrC1=CC=CC=C1I OIRHKGBNGGSCGS-UHFFFAOYSA-N 0.000 description 1
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalene Chemical compound C1=CC=C2C(C=3C4=CC=CC=C4C=CC=3)=CC=CC2=C1 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical compound CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 description 1
- IANXAXNUNBAWBA-UHFFFAOYSA-N 2,2,3-trimethylundecane Chemical compound CCCCCCCCC(C)C(C)(C)C IANXAXNUNBAWBA-UHFFFAOYSA-N 0.000 description 1
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- BKFSUZNMFPCJNJ-UHFFFAOYSA-N 2-hydroxy-3,4-dimethylidenecyclohexa-1,5-diene-1-carboxylic acid Chemical compound OC(=O)C=1C=CC(=C)C(=C)C=1O BKFSUZNMFPCJNJ-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012327 Ruthenium complex Substances 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- IQOYANWSFLVSLV-UHFFFAOYSA-N [Bi].C(C)(C)O Chemical compound [Bi].C(C)(C)O IQOYANWSFLVSLV-UHFFFAOYSA-N 0.000 description 1
- JZRMZBJSHYWPKG-UHFFFAOYSA-N [Ru+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] Chemical compound [Ru+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] JZRMZBJSHYWPKG-UHFFFAOYSA-N 0.000 description 1
- 229950003769 acefylline Drugs 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- YADDYKXZVNQFBH-UHFFFAOYSA-N argon;hydrobromide Chemical compound [Ar].Br YADDYKXZVNQFBH-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical compound C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- RYHBGVSBFUOHAE-UHFFFAOYSA-N piperazin-1-ium;bromide Chemical compound Br.C1CNCCN1 RYHBGVSBFUOHAE-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001055 reflectance spectroscopy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 125000006839 xylylene group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Hydrogenated Pyridines (AREA)
Description
201033181 六、發明說明: 【發明所屬之技術領域】 本發明係關於1-[2-(2,4-二甲苯硫基)苯基]哌啡之製造 及純化。 【先前技術】 以WO 03/029232及WO 20〇7/144〇05公開之國際專利 申請案揭示化合物1_[2_(2,4_二曱苯硫基)_苯基]哌畊及其鹽 對企清素轉運體及血清素受體3及ΙΑ (5-HT3及5_ht ) 具有親和力。此藥理學特徵使得使用該等化合物治療諸如 抑鬱症及焦慮症之情緒異常症具有吸引力。實際上,當前 正對該化合物治療情緒異常症進行臨床試驗。 藥品製造為具有很多有關活性醫藥成份(API)之品質 /純度之準則及規則的高度管制領域。因此要求製造途徑確 保最終產物之高純度,一種達成此目標之方法為研發特定 純化步驟。 結晶及再結晶為提供經純化化合物之熟知方法。w〇 2007/144005中所提供之實施例揭示二曱苯硫基)_ 苯基]哌畊及其鹽可自諸如乙酸乙酯、乙酸乙酯/水、水及甲 苯之溶劑中結晶。 【發明内容】 本發明人已發現,在1-[2-(2,4-二甲苯硫基)_苯基;|哌畊 及其醫樂學上可接受之鹽之合成中包括一個步驟(在該步 驟中由卜[2-(2,4-二曱苯硫基)-苯基]痕口井_HBr製備 1-[2-(2,4-二曱苯硫基)-苯基]哌畊_HBr異丙醇溶劑合物)可 3 201033181 移除或減少雜質且從而提供經純化之丨_r _ ί^ΊΖ’4·二甲苯硫 基)-苯基]旅畊及其醫藥學上可接受之鹽,例如心形式之 鹽。 因此,在一具體實例中,本發明提供一種製造1[2_(2 4 二曱苯硫基)苯基]哌畊或其醫藥學上可接受之鹽的方法,’气 方法包括藉由將1-[2-(2,4-二曱苯硫基)苯基]哌畊汨以鹽= 解於包含超過65% (ν/ν)之異丙醇之溶劑中獲得溶液:: 驟。 ’ 在一具體實例中,本發明提供一種製造卜口-^〆-二甲 苯硫基)苯基]哌畊或其醫藥學上可接受之鹽的方法,該方法 包括使1 -[2-(2,4-二甲苯硫基)苯基]哌畊-HBr異丙醇溶劑合 物自包含超過65% ( Wv)之異丙醇之溶劑中沈澱之步驟。 在一具體實例中,本發明係關於一種製造— 甲苯硫基)苯基]哌畊或其醫藥學上可接受之鹽之方法,該方 法包括將1-[2-(2,4-二甲苯硫基)苯基]哌畊_HBr異丙醇溶劑 合物溶解於不與該化合物形成穩定溶劑合物之溶劑中的步 驟。 在一具體實例中,本發明提供一種為二甲笨 硫基)苯基]哌畊_HBr異丙醇溶劑合物之化合物。 【實施方式】 本發明係關於一種可用於製造^[2-(2,4-二甲苯硫基) 苯基]哌畊及其醫藥學上可接受之鹽的純化步驟。以下描繪 1 _[2·(2,4-二甲笨硫基)苯基]0辰啡之分子結構 201033181
詳言之,醫藥學上可接受之鹽為無毒酸之酸加成鹽。 該等鹽包括由有機酸(諸如順丁烯二酸、反丁烯二酸、苯 甲酸、抗壞血酸、琥珀酸、草酸、雙亞甲基柳酸、甲磺酸、 〇 乙一磧酸、乙酸、丙酸、酒石酸、柳酸、檸檬酸、葡萄糖 酸、乳酸、蘋果酸、杏仁酸、肉桂酸、甲基順丁烯二酸、 天冬胺酸、硬脂酸、棕橺酸、衣康酸(itaconic acid)、乙 醇酸、對胺基苯甲酸、麩胺酸、苯磺酸、茶鹼乙酸以及8_ 鹵茶鹼(例如8-溴茶鹼))形成之鹽。該等鹽亦可由無機 鹽(諸如氫氣酸、氫溴酸、硫酸、胺基磺酸、磷酸及硝酸) 形成。尤其提及由乳酸、甲磺酸、順丁烯二酸、反丁烯二 酸、内消旋酒石酸、(+)-酒石酸、(·)_酒石酸、氯氯酸、氮 ©溴’酸、硫酸、填酸及硝酸形成之鹽。特別提及氮漢酸鹽。 如WO 2007/144005中所顯示,Wy(2,4_二甲苯硫基) 笨基]哌畊之HBr鹽晶體呈多晶型且以(至少)三種不同形 式存在,亦即α -、沒_及r _形式(、以…及 ga^na-form )。依據Dsc及溶解度數據判斷1 _形式為最 穩定形式,且其可由位於約6 86、9 73 …之獅反射加以特性化+形式之XRpD圖案示(於 圖1中。請參見製備Θ·形式之^(^二曱苯硫基)苯基] 哌畊-HBr之實施例1。 5 201033181 該化合物之製造方法揭示於WO 03/029232及 WO 2007/144005中。一種製造方法係利用可製備N-芳基鍵的 Buchwald紅催化法(參見US 5,576,460 )。在此方法中, 在高pH下將2,4-二甲基硫酚、2-溴-1-碘苯及哌畊與鈀源及 膦配位體於例如甲苯之適合溶劑中一起混合。可使用其他 二鹵苯且可保護旅π井。適合把源包括Pd2dba3、Pddba:及 Pd(OAc)2。dba為二亞苄基丙酮之縮寫。尤其提及Pddba2。 適合膦配位體包括單牙及雙牙配位體,諸如外消旋2,2,-雙-二苯基磷烷基_[1,1’]聯萘(rac-BINAP) 、1,1’-雙(二苯基膦 〇 基)二茂鐵(DPPF)、雙-(2-二笨基膦基苯基)醚(DPEphos)、 三-第三丁基膦(Fu氏鹽)、聯苯-2-基-二-第三丁基-膦、 聯苯-2-基-二環己基-膦、(2’-二環己基磷烷基-聯苯-2-基)-二曱基-胺、[2’-(二-第三丁基-磷烷基)-聯苯-2-基]-二甲基-胺及一壞己基_(2',4^6,-二丙基-聯苯-2-基)-填烧。此外,可 使用諸如氯化1,3-雙-(2,6-二-異丙基-苯基)-311-咪唑-1-鏽之 碳烯配位體替代膦配位體。詳言之,rac_BINAP為適用配位 體。添加鹼至反應混合物中可增大或提高pH。詳言之,可 ® 使用選自NaO(t-Bu)、KO(t-Bu)及Cs2C03之鹼。亦可應用 諸如1,8-二氮雜雙環[5.4.0]十一-7-烯(〇611)及1,4-二氮雜 一環[2.2_2]辛烧(DABCO )之有機驗。尤其提及NaO(t-Bu) 及 KO(t-Bu)。 或者’可在第一步驟中使硫酚及二鹵苯反應以獲得苯 硫基苯基,可將其分離’之後與β底讲或經保護之n底啡進一 步反應以獲得所要產物。 6 201033181 為獲得l-[2-(2,4-二甲苯硫基)苯基]哌畊之所要鹽,可 使以上方法中所獲得之相應自由鹼與適當酸反應以使鹽沈 殿。詳言之,可使用氫溴酸水溶液使4-二甲苯硫基) 苯基]派讲-HBr沈殿。 本發明提供一種可在例如製造途徑之此步驟使用的純 化方法。該方法提供一種經高度純化之終產物,且此外, 該方法允許使用低純度起始物質。總之,將HBr鹽溶解於 包含異丙醇之溶液中,使相應異丙醇溶劑合物自該溶液中 ® 沈澱。據本發明者之經驗,若溶液包含超過65% ( v/v )之 異丙醇,則形成異丙醇溶劑合物。可藉由冷卻產生沈澱。 隨後將異丙醇溶劑合物溶解於不形成溶劑合物之溶劑中, 且可例如藉由蒸餾移除或減少異丙醇及/或水。移除或減少 異丙醇可用以增加產率。最後使二曱苯硫基)苯基] 哌畊-HBr沈澱。可選用用於沈澱之溶劑及條件(例如溫度 變化率、晶體接種)控制所得晶體形式,術語「不形成溶 〇 劑合物之溶劑」意指不參與形成二曱苯硫基)苯基] 哌畊-HBr鹽之穩定溶劑合物的溶劑。實例包括水、thf(四 乳吱味)、二甲苯、苯、甲醇、乙醇、丙嗣及甲苯及其混 合物。尤其提及甲苯與水之混合。尤其提及水中包含超過 80%之甲苯之混合物。 藉由使相應溶劑合物沈澱來純化並不常見,且如 Hilfiker,R.(編者).P〇Iym〇rphism in 加 刪⑽㈤ W赠y. WUey-VCH,2_.(第12·π頁)中所論述,一般僅 田待’、屯化之產物難以呈無溶劑形式結晶時,推薦該純化步 7 201033181
右所要鹽不同於HBr鹽,則可依其他方法使用經純化 HBr鹽作為起始物質,其中冑HBr鹽溶解視情況獲得自 由鹼形式且藉由適當酸沈澱來獲得所要鹽。 在一具體實例中,本發明提供一種製造Μ2-(2,4·二曱 笨硫基)苯基]哌畊或其醫藥學上可接受之鹽之方法,該方法 包括藉由在諸如回流溫度之高溫下將二甲苯硫基) 苯基]哌畊-HBr鹽溶解於包含超過65% (v/v)之異丙醇之 /令劑中獲得溶液之步驟。或者,不升高溫度,而此會延長 處理時間。詳言之’該醫藥學上可接受之鹽為冷-形式之 鹽。在一具體實例中,該溶劑包含超過85% ( v/v )之異丙 醇。 在一具體實例中,本發明提供一種製造二甲 苯硫基)苯基]哌畊或其醫藥學上可接受之鹽之方法,該方法 包括例如藉由冷卻而使二曱苯硫基)笨基]哌畊 •HBr異丙醇溶劑合物自包含超過65% ( v/v)之異丙醇之溶 劑中沈澱之步驟。詳言之,該醫藥學上可接受之鹽為卢_形 式之HBr鹽。在一具體實例中,該溶劑包含超過85% ( v/v ) 之異丙醇。 在一具體實例中,本發明提供一種製造卜[2-(2,4-二曱 苯硫基)笨基]哌畊或其醫藥學上可接受之鹽之方法,該方法 包括將1-[2-(2,4-二甲苯硫基)苯基]哌畊_HBr異丙醇溶劑合 物/合解於不形成溶劑合物之溶劑中、隨後使二曱 笨硫基)苯基]哌畊-HBr沈澱之步驟。詳言之,該醫藥學上 201033181 可接受之鹽為HBr鹽,諸如冷-形式。 在一具體實例中,本發明提供一種製造二甲 苯硫基)苯基]哌畊或其醫藥學上可接受之鹽、尤其形式 之HBr鹽的方法,該方法包括以下步驟·· a )藉由例如在高溫(諸如回流溫度)下將丨_[2·(2,4_ 二曱苯硫基)苯基]哌畊-HBr溶解於包含超過65%( ν/ν)(諸 如超過85% ( v/v ))之異丙醇的溶劑中來獲得溶液; b) 例如藉由冷卻使^[2-(2,4-二甲苯硫基)苯基]哌畊 -HBr異丙醇溶劑合物自該所得溶液中沈澱; c) 將1-[2-(2,4-二甲苯硫基)苯基]哌畊_HBr異丙醇溶劑 合物溶解於不形成溶劑合物之溶劑中;詳言之,該不形成 溶劑合物之溶劑包含超過80% (諸如超過90% )之甲苯; 及 d) 例如藉由冷卻使二甲苯硫基)苯基]哌畊 -HBr自c )所得之溶液中沈澱; 若a)所用之HBr鹽含有大量雜質,則宜將b)所得之 異丙Sf· ί·今劑&物再〉谷解於包含超過6 5 %異丙醇之溶劑中, 隨後如b)中所述進行沈澱。 在一具體實例中’本發明係關於一種藉由上述方法之 一直接獲得之產物。 在一具體實例中’本發明係關於一種自固體丨_[2_(2,4_ 二甲苯硫基)苯基]哌畊-HBr鹽或卜[2-(2,4-二曱苯硫基)苯 基]哌畊-HBr之溶液中移除或減少雜質的方法,該方法包括 以下步驟: 9 201033181 a )視情況將包含超過65%( v/v )(諸如超過85%( v/v )) 之異丙醇的溶劑與固體卜[2-(2,4-二曱苯硫基)苯基]旅0井 -HBr或1_[2-(2,4_二曱苯硫基)苯基]哌畊HBr之溶液混合, 適當時例如隨後加熱,獲得1 _[2-(2,4-二曱苯硫基)苯基]11 底 畊-HBr之溶液; b )冷卻該所得溶液以使卜[2-(2,4-二曱苯硫基)苯基]t»辰 時-HBr異丙醇溶劑合物沈澱; c) 將1-[2-(2,4-二曱苯硫基)苯基]β底讲- HBr異丙醇溶劑 合物溶解於不形成溶劑合物之溶劑中;及 d) 例如藉由冷卻使^[2-(2,4-二甲苯硫基)苯基]哌畊 -HBr自c )所得之溶液中沈澱; 詳言之’ c )所用之不形成溶劑合物之溶劑係選自水、 THF、二甲苯、苯、曱醇、乙醇、丙酮及曱苯及其混合物。 尤其提及曱苯與水之混合,尤其包含超過8〇% ( v/v )(諸 如超過90%(v/v))之甲苯。 該等雜質之實例包括鈀(Pd) 、ΐ·[2-(2,4-二甲基-笨硫 基)-苯基]-4-(2-哌畊_1_基-苯基)_哌畊(化合物丨)、1[2_仏 氣-2,4-二甲基-苯硫基)苯基]哌畊(化合物2)、 二甲苯硫基)苯基]哌畊(化合物3)及卜[2_(2,4_二甲苯硫基) 笨基]哌畊-HBr第三丁醇溶劑合物,亦參見圖4_6。鈀為使 用Pd催化劑所產生之雜質。「Pd」或「鈀」欲指所有含有 之化合物。化合物里為在兩個哌畊氮處經催化而形成 N-芳基鍵時所產生之雜質。化合物2及3為可能被相應^ 氣或2,5-二甲基化合物污染< 2,二甲基硫酚原材料所攜 201033181 帶之雜質。由於反應中使用第三丁醇鈉,因此會形成第三 丁醇溶劑合物。 一 為進一步說明本發明,以下描述可能有幫助。將 1-[2-(2,4-二曱苯硫基)苯基]哌畊-HBr ( A)饋入反應器中'。 添加異丙醇(l〇-15L/kgA)及水(〇3_1〇L/kgA)且開始 攪拌。加熱混合物至回流且溶解所有^(2,4·二曱苯硫基)苯 基]哌畊ΗΒγ鹽。使溶液冷卻至<2〇t,且過濾晶體(異丙 醇溶劑合物)且用異丙醇(總共2.4_2.6L/kgA)洗滌兩次。 將濕濾餅再饋入反應器中且添加曱苯(4-6 L/kg A )。將濕 濾餅中之異丙醇/水共沸餾出且隨同水(〇2 〇·3χΑ) 一起添 加蒸餾中所損耗之曱苯。加熱混合物至回流且溶解所有 1-(2,4-二曱苯硫基)苯基]哌畊_HBr。使溶液冷卻至<2〇°c , 且過濾晶體且用甲苯(總共丨.0-4.0 L/kg A)洗滌兩次。使 晶體在例如60。(:之高溫及真空下脫水。獲得冷-形式之 ^2,4-二曱苯硫基)苯基]略啡-HBr。 如實施例5所顯示,本發明之純化方法優於等效再結 晶方法之處在於可減少或移除更多雜質。因此,本發明之 純化方法具有獨特且不可預見之品質。 如上所說明,1-(2,4-二曱苯硫基)苯基]哌畊-HBr異丙 醇溶劑合物適用於純化二甲苯硫基)苯基]哌畊及其 醫藥學上可接受之鹽之方法步驟。 因此’在一具體實例中,本發明係關於一種包含1-(2,4- 一甲笨硫基)苯基]哌畊於超過65% (v/v)之異丙醇中之液 體溶液。 11 201033181 在一具體實例中,本發明係關於1-(2,4-二甲苯硫基)苯 基]哌畊-HBr異丙醇溶劑合物。 在一具體實例中,本發明係關於具有位於約6.44、 8.13 ' 8.77、10.41 ( °2㈠之XRPD反射(例如具有如圖2 所示之XRPD圖案)之W2,4-二甲苯硫基)苯基]哌畊-HBr 異丙醇溶劑合物。 應庄思使用1-(2,4-一曱苯硫基)苯基]0辰啡_jjBr異丙醇
溶劑合物之另一益處與其處理特性有關。溶劑合物不穩定 且易用過濾器處理。 本文所引用之所有參考文獻均以全文引用的方式併入 本文中,且該引用的程度就如同已個別地及特定地指示將 各參考文獻以全文引用的方式併入且陳述於本文中一俨 (達法律所允許之最大程度),不論本文中別處單別提= 之任何特定文獻之併入。 π ,入%糊低蜩,古則描述本 之上下文中所用之術語「-(a、」及「該(the)
類似如不物視為涵蓋單數與複數。舉例而言,除非另 明,否則應瞭解「玆仆人私,a 笏化。物(the Compound)」一詞係 發月或特定描述之態樣的各種化合物。 ^另外指明,否則本文所提供之所有精確值均 表相應近似值「γ ( ^ - ,針對特定因素或量測所提供之所; 修飾)。 見為提供相應近似量測,適當時藉由「; 除非另外說明 或與上下文明顯抵觸 否則本文中針| 12 201033181 要素使用諸如「包含」、「具有」、「包括」或「含有」 之術語之本發明態樣的說明意欲證實本發明之類似態樣 「由彼或彼等特定要素組成」、「基本上由彼或彼等特定 要素組成」或「實質上包含彼或彼等特定要素」(例如除 非另外說明或與上下文明顯抵觸,否則本文描述包含特定 要素之組成物應瞭解亦描述由元素組成之组成物)。 實施例 Ο 分析方法 ]H NMR ^ i§ 經 Bruker Avance DRX500 儀在 500.13 MHz下記錄。二甲亞砜(99.8%D)用作溶劑,且將四甲基 矽烷(TMS )用作内部參考標準物。 使用差示掃描熱量測定法(D S C )量測溶點。設備為 TA-Instruments DSC-Q1000’ 其以 5Vmin 校準以得到熔點 作為初始值。將約2 mg樣品於鬆閉合盤中、在氮氣流下以 5 ° /min 加熱。 Q 用於估計脫水物質之溶劑/水含量之熱解重詈分;|:彳_ XJTGA)係使用 TA- Instruments TGA-Q500 進行。將 i_i〇 mg 樣品在開口盤中、在氮氣流下以1 〇。/min加熱。 2L光粉末繞射圖(XRPD )後經使用CuK α !輻射的 PANalytical X’Pert PRO X射線繞射儀量測。使用 X'celerator偵測器、在5-40 °之20範圍中、以反射方式量 測樣品。繞射數據以±0.1 (。2 0 )表示。 1^(2,4-二甲苯硫基)苯基1哌口丼-HBr之純唐徭推用梯度 逆相HPLC方法、應用Luna笨基己基管柱(150x4.6 mm、 13 201033181 # m粒度)來測定。移動相由純化水及用三氟乙酸酸化 之乙腈組成。流動速率1 ·〇 mL/rnin、管柱烘箱4(TC、注射 體積50 #L。使用226 nM之UV偵測定量峰面積。 趾係使用Varian Vista PRO ICP-OES (感應耦合電漿 原子反射光譜分析)來定量分析。波長:340.458 nm、342.122 nm、360.955 nm 〇 f施例1 :製備石-形式之1-(2.4-二甲茉硫基)苯基1哌a# -HBr,參艮 WO 2007/144005 夕實施例 4c 將49.5公克l-[2-(2,4-二曱苯硫基)-苯基]哌畊無色油 狀物溶解於500 mL乙酸乙酯中且添加18.5 mL 48 wt%之 HBr (水溶液)。此添加導致形成稠漿液,在室溫下攪拌隔 夜。過濾且真空脫水(50°C )隔夜,產生29.6公克呈白色 固體狀之產物(47%)。 NMR 符合結構。元素分析:56.86°/。C,7.3 5% N, 6.24% H(l:l 之鹽的理論值:56.99% C,7.3 9% N,6.11% H)。 實施例2 :特性化厶-形式之1-(2,4-二甲笨硫基)茉基1 哌姘-HBr,泉自.WO 2007/144005之實施例4d 如實施例1所製備之/5形式之氫溴酸鹽為結晶體 (XRPD),參見圖1。其熔點為約23 1°C。其當曝露於高 相對濕度時吸收約0.6%之水且於水中之溶解度為1.2 mg/mL。 會施例L fl備1-(2,4-二甲笨硫基)笨基1哌讲-HBr里而 醇溶劍合物 加熱1-(2,4-二甲苯硫基)苯基]哌畊-HBr ( 25 g)於異丙 201033181 醇(250 mL)中之溶液,產生稠懸浮液,再添加異丙醇(25 mL )及水(25 mL )且將懸浮液加熱至回流得到溶液。將溶 液空白過濾、經冰浴冷卻且過濾。所得產物在5〇5>c下真空 脫水。 實施例~~生·特性化~~Li(2,4-二甲苯硫基基ι〇底讲.HBr 異丙醇溶f!丨合物 異丙醇溶劑合物(例如實施例3中所製備之異丙酵溶 劑合物)為結晶體(XRPEO ,參見圖2。TGA顯示在8(TC 緩慢開始脫去溶劑,且在12(rc完全脫去溶劑。重量損失經 量測達12.2%。DSC顯示對應於去溶劑化之吸熱。去溶劑化 之後’形成225 C炼融之無溶劑結晶鹽。所加熱樣品之xprd 顯示,此為α形式(對於α -形式之定義參見w〇 2007/144005 ) 。α -形式接著部分再結晶為在23〇χ:熔融之 形式,可能為冷-形式》TGA及DSC熱分析圖顯示於圖3 中 〇 ❿ 宜施例5 :繞土i 1-(2,4-二甲苯踹基)裟篡 用於此實施例中兩種方法之起始物質為含有化合物1 (4.8%)、化合物 2( 0.19%)及化合物 3 ( 0.18%)之 1-(2,4-'一甲本硫基)苯基]旅啡- HBr。 將1-(2,4-二甲苯硫基)苯基]旅啡_HBr( 33.1 Kg)於異 丙醇(412 L)與水(18 L)之混合物中加熱至回流。使溶 液冷卻至20°C且藉由過濾分離^(2,^二甲苯硫基)苯基]哌 畊之異丙醇溶劑合物且用異丙酵(82 L )洗滌。在回流下將 濕滤餅溶解於異丙醇(353 L)與水(17 L)之混合物中。 15 201033181 使溶液冷卻至20°C且藉由過濾分離i_(2,4-二甲苯硫基)苯 基]旅啡之異丙醇溶劑合物且用異丙醇(74 l )洗滌。在80 C將濕遽餅溶解於甲苯(132]L)與水(13 L)之混合物中 且空白過渡。自反應器中蒸餾出水及異丙醇(55L),當餾 出物達1 021時停止蒸餾。接著添加水(7 l )且使溶液緩 慢冷卻至20。(:。藉由過濾分離二甲苯硫基)苯基]哌 啡-HBr ’用甲苯(77 L )洗滌濾餅且脫水。雜質含量如下: 化合物1小於0.05%,化合物2小於〇〇15%及化合物3小 於 0.05%。 為了比較,亦使用以下方法純化起始物質。將1 g l-(2,4-二曱苯硫基)苯基]哌畊_jjBr於甲苯(10 mL)中加熱 至回流。接著添加水(0.6 mL )且將溶液加熱至回流得到澄 清溶液。使此溶液冷卻至約2〇°c,接著經冰浴進一步冷卻。 藉由過渡分離1-(2,4-二甲苯硫基)苯基]哌畊·ΗΒγ,且於真空 烘箱中脫水得到(0.9 g)。 雜質含量如下:化合物1佔4%,化合物2佔0.15%及 化合物3佔0.14%。 實施例6 :純化—1^1·二甲茉葙某、芏某1畈崎-HRr 用於此實施例之1-(2,4-二甲苯硫基)苯基]哌畊HBr批 料含有化合物1 (0_5%)。 將114 kg HBr鹽於異丙醇(丨424 L)與水(64 L)之 混合物中加熱至回流。使溶液冷卻且藉由過濾分離^(2,^ 二甲苯硫基)苯基]哌畊-ΗΒγ異丙醇溶劑合物。在8〇。€下將 溶劑合物溶解於甲苯(513 L)與水(5〇 L)之混合物中且 201033181 空白過滤。蒸餾出水及異丙醇, ^ — 儿备餾出物達102°C時停止 蒸德。添加水(2 7 L)且估.、办、—a ,、 )且使溶液冷卻至2〇°C且藉由過渡分 離1-(2,4-二曱苯硫基)苯基]哌诽 田田w 个恭用甲笨洗滌濾餅。分 析最終產物顯示化合物i小於〇 J於U.05 /。,且XRDp數據證實獲 得冷-形式。 實施_例7 製造及純化1_ρ ,, _ α, γ r. u , n —T -查疏基)茉某1哌of -HBr 在氮氣氛圍下,在室溫下攪拌pddba2 (2u mg,〇 Μ? mm〇1)、BINAP ( 458 mg,Μ% 咖〇1)、第三 丁醇納(% 〇 g)、派讲(27.5g)及甲苯(185mL)約3〇分鐘。向此混 合物中添加1-演-2-破苯(12 mL)及2,‘二甲基硫酚(i2 3 mL )且不加熱而擾拌反應混合物約6〇分鐘。接著在回流下 加熱反應混合物5小時,且接著添加水(7〇 mL ),隨後再 攪拌5分鐘’接著分離各相(大於6〇°c之溫度)。用氯化 鈉溶液洗滌甲苯相2次。向溫熱甲苯相中添加氫漠酸48% (16.2 g )’添加種晶(HBr /5 -形式)且使溶液冷卻。藉 由過濾分離1-(2,4-二曱苯硫基)苯基]哌畊_HBr ,且用甲笨 (160 mL)及水(190 mL)洗務濾餅。分析脫水之濾餅樣 品顯示0.64%化合物1及70 ppm Pd。濕濾餅於異丙醇(345 mL )中、在回流溫度下加熱且空白過濾熱溶液。使澄清溶 液冷卻至室溫以下,藉由過濾分離1-(2,4-二曱苯硫基)苯基] 哌畊-HBr之異丙醇溶劑合物’用異丙醇(40 mL )洗務且在 40°C下真空脫水。分析顯示化合物1 ( 0.05%)及2 ppm Pd。 將l-(2,4-二甲苯硫基)苯基]哌畊-HBr異丙醇溶劑合物 17 201033181 (19.5 g )、曱苯(100 mL )及水(5 mL)加熱至回流溫度, 且藉由蒸餾(23 mL)移除水及異丙醇。添加曱苯(23 mL) 且使溫度升尚至回流溫度’隨後添加水(1 〇 m L )且使溶液 冷卻至室溫。藉由過濾分離1-(2,4-二曱苯硫基)苯基]哌畊 -HBr ’用冷曱苯(70 mL )洗滌且在5〇。〇下真空脫水。分析 顯示低於0.05%之化合物1及1 ppm之pd。XRDP數據證實 獲得/3 -形式。 f施例8 :製造及純化1-(2,4-二甲茉硫基)笨基1旅_ 〇 將 1000 g Pddba2、3600-4600 g BINAP、270-310 kg 第 三丁醇鈉、360-420 kg哌畊及1300-1500 L甲苯饋入反應器 中’且攪拌混合物至少30分鐘。添加210-214 kg 1-溴-2-峨苯及99.5-100.5 kg 2,4-二甲基硫酚且將所得混合物在低 於25°C下攪拌至少60分鐘。使溫度升高至80-951:歷時至 少13小時。使混合物冷卻,添加1〇〇〇_12〇〇 l水,且分離 各相。用總計1 070-1 140 kg約150/〇之NaCl洗滌甲苯相若干 次。添加126-128 kg HBr 48%及40-46 L水,且加熱混合物 ❹ 直至獲得完全澄清之溶液。藉由冷卻獲得標題化合物之粗 晶體。藉由過濾分離晶體’且用10004200 [甲苯及400-700 L水洗務晶體。將濾餅溶解於3〇63_3112 [異丙醇中且空白 過濾所得溶液。加熱溶液,且蒸餾出247〇_2964 L,接著添 加145 7-15 07 L異丙醇。藉由加熱獲得完全溶解,且藉由冷 卻獲得異丙醇溶劑合物之晶體。藉由過濾分離晶體,隨後 用865-914 L異丙醇洗丨條。 18 201033181 將200 kg l-(2,4-二甲苯硫基)苯基]哌畊_HBr異丙醇々 劑合物添加至980-1020 L甲苯及48_52 L水中。加熱溶ς 晶體且空白過濾該溶液。蒸餾溶液直至蒸氣溫度高於 l〇2°C,且添加與餾出物之體積等量之甲苯。再添加48 52 l 水且加熱液體直至完全溶解。藉由冷卻及接種使卢形式之 1-(2,4-二甲苯硫基)苯基]哌畊-HBr結晶。 【圖式簡單說明】 圖1 :心形式之1-[2-(2,4-二甲苯硫基)苯基]哌畊-HBr ❹
之 XRPD
圖2:卜[2-(2,4-二甲苯硫基)笨基]哌畊-HBr異丙醇溶 劑合物之XRPD 圖3: 1-[2-(2,4-二甲苯硫基)苯基]派啡- HBr異丙醇溶 劑合物之TGA及DSC熱分析圖 圖4: ι_[2-(2,4-二甲基_苯硫基)_苯基]-4-(2-娘讲-1-基- 苯基)-娘畊 圖5: ι_[2-(5-氯-2,4_二曱基_苯硫基)笨基]0辰讲 ◎圖6:卜[2-(2,6-二甲苯硫基)笨基]派畊 【主要元件符號說明】 無 19
Claims (1)
- 201033181 七、申請專利範圍: 1·—種製造1-[2-(2,4-二甲苯硫基)苯基]旅啡或其醫藥 學上可接受之鹽之方法’該方法包括藉由將二甲 苯硫基)苯基]哌啡-HBr鹽溶解於包含超過65% ( v/v )之異 丙醇之溶劑中獲得溶液之步驟。 2. 如申請專利範圍第1項之方法,其中該醫藥學上可接 受之鹽為HBr鹽。 3. 如申請專利範圍第2項之方法,其中該醫藥學上可接 受之鹽為/3-形式之HBr鹽。 4. 如申請專利範圍第1項至第3項中任一項之方法,其 中該溶劑包含超過8 5 % ( v/v )之異丙醇。 5. 如申請專利範圍第1項至第4項中任一項之方法,該 方法包含使1-[2-(2,4-二甲苯硫基)苯基]派畊-HBr異丙醇溶 劑合物自該溶液中沈澱之後續步驟。 6·—種製造1-[2-(2,4-二甲苯硫基)苯基]哌畊或其醫藥 學上可接受之鹽之方法,該方法包含使1-[2-(2,4-二曱苯硫 基)苯基]哌畊-HBr異丙醇溶劑合物自包含超過65% ( v/v ) 之異丙醇的溶劑中沈澱之步驟。 7. 如申請專利範圍第6項之方法,其中該醫藥學上可接 受之鹽為HBr鹽。 8. 如申請專利範圍第7項之方法,其中該醫藥學上可接 受之鹽為/3-形式之HBr鹽。 9. 如申請專利範圍第6項至第8項中任一項之方法’其 中該溶劑包含超過85% ( v/v)之異丙醇。 201033181 10.一 種製造 l-[2-(2 4 -田 # 泣 is 學上可接受之鹽之方法二:本基)本基]料或其醫藥 — 該方法包含將1-[2-(2,4-二甲苯硫 土 ):基]哌畊HBr異丙醇溶劑合物溶解於不形成溶劑合物 之溶劑中、隨後使1_[2 殿之步驟。 ’ ·—甲U)本基㈣撒沈 11.如申請專利範圍箆1n 固弟10項之方法,其中該不形成溶劑 曱 甲醇、乙醇、丙 〇 合物之溶劑係選自水、THF 酮及甲苯及其混合物 M12·如巾請專利範圍第11項之方法,其中該不形成溶劑 σ物之溶劑包含超過80〇/〇之甲苯。 13·如申請專利範圍第1〇項之方法,其中該醫藥學上可 接受之鹽為HBr鹽。 14. 如申請專利範圍第13項之方法,其中該醫藥學上可 接又之鹽為形式之HBr鹽。 15. 如申請專利範圍帛!項之方法’該方法包括 驟: a) 藉由將1-[2·(2,4_二甲苯硫基)苯基]哌畊4&溶 解於包含超過65% ( ν/ν )之異丙醇的溶劑中獲得溶液. b) 使1-[2-(2,4-二甲苯硫基)苯基;|哌畊_HBr異丙醇 溶劑合物自該所得溶液中沈澱; c) 將1-[2-(2,4-二曱苯硫基)苯基]η辰啡_HBr異丙醇 溶劑合物溶解於不形成溶劑合物之溶劑中;及 d) 使1-[2-(2,4-二曱苯硫基)苯基]派啡_jjBr自c) 所得之溶液中沈澱。 21 201033181 16·如申明專利範圍第15項之方法,其中步驟a)中之 該溶劑包含超過8 5 0/广 、 /〇(v/v)之異丙醇,且步驟c)中之該 不形成溶劑合物之溶劑包含超過80% (v/v)之甲苯。 17·如申請專利範圍第15項或第16項之方法,其中該 醫藥學上可接受之鹽為HBr鹽。 18. 如申請專利範圍第17項之方法,其中該醫藥學上可 接受之鹽為沒-形式之HBr鹽。 19. —種自固體^[2-(2,4-二曱苯硫基)苯基]哌畊·ΗΒγ 中或自1-[2-(2,4-二甲苯硫基)苯基]略畊_HBr之溶液中移除 ◎ 戒減少雜質的方法,該方法包括以下步驟: a )使包含超過65 % ( v/v )之異丙醇的溶劑與固體 1-[2-(2,4-二甲苯硫基)苯基]〇底畊_HBr或與1-[2-(2,4-二 甲苯硫基)苯基]哌畊-HBr之溶液混合以獲得ι_[2-(2,4-二甲苯硫基)苯基]哌畊-HBr之溶液;及 b) 冷卻該所得溶液以使1-[2-(2,4_二甲苯硫基)苯基] 哌畊-HBr異丙醇溶劑合物沈澱; c) 將1-[2-(2,4-二甲苯硫基)苯基]哌畊-HBr異丙醇 ◎ 溶劑合物溶解於不形成溶劑合物之溶劑中;及 d) 使1-[2-(2,4-二甲笨硫基)苯基]哌畊-HBr自步驟 c)所得之溶液中沈澱。 20. 如申請專利範圍第19項之方法,其中該雜質係選自 卜[2-(2,4-二甲基-苯硫基苯基]-4_(2_α底口井-1 -基苯基)-0辰口井 或其鹽;1-[2-(5-氯-2,4-二曱基-苯硫基)苯基]哌畊或其鹽; 卜[2-(2,6-二甲苯硫基)苯基]派畊或其鹽 ;或纪。 22 201033181 21. —種液體溶液,其包含1-(2,4-二曱苯硫基)苯基]哌口井 於超過65% ( v/v)之異丙醇中。 22. —種化合物,其為1-[2-(2,4-二曱苯硫基)苯基]哌畊 -HBr異丙醇溶劑合物。 23. 如申請專利範圍第22項之化合物,該化合物具有位 於約 6.44、8.13、8.77、10.41 ( 02θ )之 XRPD 反射。 24. 如申請專利範圍第23項之化合物,其具有如圖2所 示之XRPD。 〇 八、圖式: (如次頁)23
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200900223 | 2009-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201033181A true TW201033181A (en) | 2010-09-16 |
Family
ID=42101395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW099103300A TW201033181A (en) | 2009-02-17 | 2010-02-04 | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8598348B2 (zh) |
| EP (1) | EP2398785B1 (zh) |
| JP (1) | JP5738774B2 (zh) |
| KR (1) | KR101639833B1 (zh) |
| CN (1) | CN102317272B (zh) |
| AR (1) | AR075436A1 (zh) |
| AU (1) | AU2010214956B2 (zh) |
| BR (1) | BRPI1006975B1 (zh) |
| CA (1) | CA2751498C (zh) |
| CL (1) | CL2011001992A1 (zh) |
| CO (1) | CO6400224A2 (zh) |
| DK (1) | DK2398785T3 (zh) |
| EA (1) | EA020473B1 (zh) |
| ES (1) | ES2441079T3 (zh) |
| HR (1) | HRP20131236T1 (zh) |
| IL (1) | IL214178A (zh) |
| MX (1) | MX2011008661A (zh) |
| NZ (1) | NZ594658A (zh) |
| PL (1) | PL2398785T3 (zh) |
| PT (1) | PT2398785E (zh) |
| RS (1) | RS53074B (zh) |
| SG (1) | SG173735A1 (zh) |
| SI (1) | SI2398785T1 (zh) |
| SM (1) | SMT201400010B (zh) |
| TW (1) | TW201033181A (zh) |
| WO (1) | WO2010094285A1 (zh) |
| ZA (1) | ZA201105992B (zh) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201403835UA (en) * | 2012-01-03 | 2014-10-30 | Lundbeck & Co As H | Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine |
| CN104797566B (zh) * | 2012-09-19 | 2017-07-07 | 桑多斯股份公司 | 沃替西汀氢溴酸盐的新结晶形式 |
| KR102171152B1 (ko) | 2012-12-13 | 2020-10-29 | 하. 룬드벡 아크티에셀스카브 | 보르티옥세틴 및 도네페질을 포함하는 조성물 |
| RS55932B1 (sr) * | 2013-02-22 | 2017-09-29 | H Lundbeck As | Postupak za proizvodnju vortioksetina |
| US20160200698A1 (en) | 2013-09-12 | 2016-07-14 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd | Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage |
| US10414741B2 (en) | 2013-09-30 | 2019-09-17 | Cadila Healthcare Limited | Amorphous vortioxetine and salts thereof |
| EP2878596A1 (en) * | 2013-11-29 | 2015-06-03 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates |
| CN103788019B (zh) * | 2014-01-22 | 2015-10-07 | 苏州明锐医药科技有限公司 | 沃替西汀的制备方法 |
| CN103788020B (zh) * | 2014-01-22 | 2015-11-04 | 苏州明锐医药科技有限公司 | 沃替西汀的制备方法 |
| EP3099669A1 (en) | 2014-01-31 | 2016-12-07 | Egis Gyógyszergyár Zrt. | Process for the preparation of vortioxetine salts |
| CN104059030B (zh) * | 2014-05-30 | 2016-05-04 | 镇江圣安医药有限公司 | [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途 |
| CN105218482B (zh) * | 2014-06-24 | 2018-04-06 | 杭州和泽医药科技有限公司 | 沃替西汀氢溴酸盐β晶型的制备方法 |
| US9687484B2 (en) | 2014-07-18 | 2017-06-27 | Dipharma Francis S.R.L. | Crystalline forms of an antidepressant compound |
| WO2016079751A2 (en) | 2014-11-17 | 2016-05-26 | Megafine Pharma (P) Ltd. | A process for preparation of vortioxetine and polymorphs thereof |
| CN105669594A (zh) * | 2014-11-19 | 2016-06-15 | 康普药业股份有限公司 | 抗抑郁症药1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的制备方法 |
| CN105801517A (zh) * | 2014-12-30 | 2016-07-27 | 上海奥博生物医药技术有限公司 | 一种沃替西汀氢溴酸盐新晶型及其制备方法 |
| WO2016125190A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof |
| EP3274330A1 (en) | 2015-03-26 | 2018-01-31 | Cipla Limited | Method for making serotonin reuptake inhibitors |
| CN105439980B (zh) * | 2015-05-08 | 2017-10-24 | 北京北陆药业股份有限公司 | 一种氢溴酸沃替西汀一仲丁醇合物及其制备方法 |
| CN105367515B (zh) * | 2015-05-08 | 2017-10-27 | 北京北陆药业股份有限公司 | 一种氢溴酸沃替西汀α晶型的制备方法 |
| CN106316985B (zh) * | 2015-06-18 | 2021-11-09 | 郑州深蓝海生物医药科技有限公司 | 一种β型高效氢溴酸沃替西汀转晶方法 |
| WO2017125504A1 (en) * | 2016-01-20 | 2017-07-27 | Amneal Pharmaceuticals Company Gmbh | Polymorphic forms of vortioxetine hydrobromide tert-butanolate |
| BR112018003930A2 (pt) | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| HUE057993T2 (hu) * | 2017-04-25 | 2022-06-28 | H Lundbeck As | Eljárás vortioxetin-HBr alfa-forma elõállítására |
| CN108017595A (zh) * | 2017-12-20 | 2018-05-11 | 安徽源久源科技有限公司 | 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN112125868B (zh) * | 2020-09-25 | 2021-08-03 | 中山万远新药研发有限公司 | 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB852974A (en) | 1958-04-17 | 1960-11-02 | Parke Davis & Co | Ethers and means for producing the same |
| FR2186237B1 (zh) | 1972-05-03 | 1975-10-31 | Synthelabo | |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| HRP20110412T1 (hr) * | 2006-06-16 | 2011-06-30 | H. Lundbeck A/S | Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova |
| EP2439201B1 (en) | 2006-06-16 | 2013-08-07 | H. Lundbeck A/S | Compounds with combined sert, 5-ht3 and 5-ht1a activity |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
-
2010
- 2010-02-04 TW TW099103300A patent/TW201033181A/zh unknown
- 2010-02-16 SG SG2011059227A patent/SG173735A1/en unknown
- 2010-02-16 BR BRPI1006975-5A patent/BRPI1006975B1/pt active IP Right Grant
- 2010-02-16 WO PCT/DK2010/050039 patent/WO2010094285A1/en not_active Ceased
- 2010-02-16 EA EA201171065A patent/EA020473B1/ru not_active IP Right Cessation
- 2010-02-16 DK DK10704890.2T patent/DK2398785T3/da active
- 2010-02-16 AU AU2010214956A patent/AU2010214956B2/en active Active
- 2010-02-16 MX MX2011008661A patent/MX2011008661A/es active IP Right Grant
- 2010-02-16 SI SI201030444T patent/SI2398785T1/sl unknown
- 2010-02-16 CN CN201080007947.5A patent/CN102317272B/zh active Active
- 2010-02-16 RS RS20130554A patent/RS53074B/sr unknown
- 2010-02-16 PL PL10704890T patent/PL2398785T3/pl unknown
- 2010-02-16 EP EP10704890.2A patent/EP2398785B1/en active Active
- 2010-02-16 NZ NZ594658A patent/NZ594658A/xx not_active IP Right Cessation
- 2010-02-16 KR KR1020117019067A patent/KR101639833B1/ko active Active
- 2010-02-16 CA CA2751498A patent/CA2751498C/en not_active Expired - Fee Related
- 2010-02-16 JP JP2011549435A patent/JP5738774B2/ja active Active
- 2010-02-16 HR HRP20131236AT patent/HRP20131236T1/hr unknown
- 2010-02-16 PT PT107048902T patent/PT2398785E/pt unknown
- 2010-02-16 AR ARP100100441A patent/AR075436A1/es not_active Application Discontinuation
- 2010-02-16 ES ES10704890.2T patent/ES2441079T3/es active Active
- 2010-02-16 US US13/148,088 patent/US8598348B2/en active Active
-
2011
- 2011-07-19 IL IL214178A patent/IL214178A/en active IP Right Grant
- 2011-08-05 CO CO11099111A patent/CO6400224A2/es not_active Application Discontinuation
- 2011-08-16 CL CL2011001992A patent/CL2011001992A1/es unknown
- 2011-08-16 ZA ZA2011/05992A patent/ZA201105992B/en unknown
-
2014
- 2014-01-22 SM SM201400010T patent/SMT201400010B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201033181A (en) | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine | |
| EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
| JP6464098B2 (ja) | ボルチオキセチンの製造方法 | |
| JP2008239629A (ja) | 新規なベンラファクシン塩酸塩多型形状、ならびにその調製方法 | |
| JP2008509953A (ja) | 4−[[(7r)−8−シクロペンチル−7−エチル−5,6,7,8−テトラヒドロ−5−メチル−4−6−オキソ−2−ピペリジニル]アミノ]−3−メトキシ−n−(1−メチル−4−ピペリジニル)ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用 | |
| CN102060753B (zh) | 一种4-苯胺基哌啶类镇痛药的精制方法 | |
| KR20190035680A (ko) | 벨리노스테트의 다형태 및 이의 제조 방법 | |
| JP2005511668A (ja) | 結晶性ベンラファキシン塩基及びベンラファキシン塩酸塩の新規多形、並びにそれらの製法 | |
| JP5564439B2 (ja) | [フェニルスルファニルフェニル]ピペリジンの製造方法 | |
| KR101557832B1 (ko) | (r)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염 | |
| TW200927739A (en) | Synthesis of quaternary salt compounds | |
| JP2025518760A (ja) | ピコリンアミド殺真菌剤化合物の結晶形態 | |
| JP2004526692A (ja) | 純粋な塩酸オンダンセトロン二水和物を製造するための改良された方法 | |
| EP2072510A1 (en) | Crystalline form of azelastine | |
| EP2199291A1 (en) | Process for preparation of pimobendan hydrochloride | |
| JP7736311B2 (ja) | ピリミジノジアゼピン誘導体の結晶性形態 | |
| JP2025083072A (ja) | ボルチオキセチンの製造方法 | |
| WO2025257758A1 (en) | Solid state forms of navacaprant | |
| KR20190005678A (ko) | O-데스메틸-벤라팍신의 신규한 니코틴산 염 및 이의 제조방법 | |
| CN121175294A (zh) | 盐酸替洛利生的多晶型形式 | |
| JP2010511679A (ja) | テナトプラゾールカリウム塩のコングロメレート | |
| HK1165955B (zh) | 1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的提纯 | |
| JP2020536951A (ja) | ステモスピロニン及びその塩の固体形態 |